Hunan Fangsheng Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 603998.SS

Hunan Fangsheng Pharmaceutical Co., Ltd. Revenue Per Share for the year ending December 31, 2023: USD 0.53

Hunan Fangsheng Pharmaceutical Co., Ltd. Revenue Per Share is USD 0.53 for the year ending December 31, 2023, a -12.69% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Hunan Fangsheng Pharmaceutical Co., Ltd. Revenue Per Share for the year ending December 31, 2022 was USD 0.60, a 5.30% change year over year.
Hunan Fangsheng Pharmaceutical Co., Ltd. Revenue Per Share for the year ending December 31, 2021 was USD 0.57, a 25.88% change year over year.
Hunan Fangsheng Pharmaceutical Co., Ltd. Revenue Per Share for the year ending December 31, 2020 was USD 0.46, a 20.63% change year over year.
Hunan Fangsheng Pharmaceutical Co., Ltd. Revenue Per Share for the year ending December 31, 2019 was USD 0.38, a 5.22% change year over year.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

Shanghai Stock Exchange: 603998.SS

Hunan Fangsheng Pharmaceutical Co., Ltd.

CEO	Ms. Xiaoli Zhou
IPO Date	Dec. 5, 2014
Location	China
Headquarters	No. 299, Jiayun Road
Employees	1,686
Sector	Health Care
Industries Pharmaceuticals

Description

Hunan Fangsheng Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products in China. It offers medicines in the form of tablets, capsules, and granules for cardiovascular and cerebrovascular, orthopedic, pediatric, gynecological, traumatology, and anti-infectives. The company was founded in 2002 and is based in Changsha, China.

Key trends

Past 5 years